Ranganath Muniyappa1, Michael J Quon. 1. Diabetes Unit, National Center for Complementary and Alternative Medicine, National Institutes of Health, Bethesda, Maryland 20892-1632, USA.
Abstract
PURPOSE OF REVIEW: Vasodilator actions of insulin are mediated by phosphatidylinositol 3-kinase dependent insulin signaling pathways in endothelium, which stimulate production of nitric oxide. Insulin-stimulated nitric oxide mediates capillary recruitment, vasodilation, increased blood flow, and subsequent augmentation of glucose disposal in skeletal muscle. Distinct mitogen-activated protein kinase dependent insulin signaling pathways regulate secretion of the vasoconstrictor endothelin-1 from endothelium. These vascular actions of insulin contribute to the coupling of metabolic and hemodynamic homeostasis that occurs under healthy conditions. Insulin resistance is characterized by pathway-specific impairment in phosphatidylinositol 3-kinase dependent signaling in both metabolic and vascular insulin target tissues. Here we discuss consequences of pathway-specific insulin resistance in endothelium and therapeutic interventions targeting this selective impairment. RECENT FINDINGS: Shared causal factors such as glucotoxicity, lipotoxicity, and inflammation selectively impair phosphatidylinositol 3-kinase dependent insulin signaling pathways, creating reciprocal relationships between insulin resistance and endothelial dysfunction. Diet, exercise, cardiovascular drugs, and insulin sensitizers simultaneously modulate phosphatidylinositol 3-kinase and mitogen-activated protein kinase dependent pathways, improving metabolic and vascular actions of insulin. SUMMARY: Pathway-specific impairment in insulin action contributes to reciprocal relationships between endothelial dysfunction and insulin resistance, fostering clustering of metabolic and cardiovascular diseases in insulin-resistant states. Therapeutic interventions that target this selective impairment often simultaneously improve both metabolic and vascular function.
PURPOSE OF REVIEW: Vasodilator actions of insulin are mediated by phosphatidylinositol 3-kinase dependent insulin signaling pathways in endothelium, which stimulate production of nitric oxide. Insulin-stimulated nitric oxide mediates capillary recruitment, vasodilation, increased blood flow, and subsequent augmentation of glucose disposal in skeletal muscle. Distinct mitogen-activated protein kinase dependent insulin signaling pathways regulate secretion of the vasoconstrictor endothelin-1 from endothelium. These vascular actions of insulin contribute to the coupling of metabolic and hemodynamic homeostasis that occurs under healthy conditions. Insulin resistance is characterized by pathway-specific impairment in phosphatidylinositol 3-kinase dependent signaling in both metabolic and vascular insulin target tissues. Here we discuss consequences of pathway-specific insulin resistance in endothelium and therapeutic interventions targeting this selective impairment. RECENT FINDINGS: Shared causal factors such as glucotoxicity, lipotoxicity, and inflammation selectively impair phosphatidylinositol 3-kinase dependent insulin signaling pathways, creating reciprocal relationships between insulin resistance and endothelial dysfunction. Diet, exercise, cardiovascular drugs, and insulin sensitizers simultaneously modulate phosphatidylinositol 3-kinase and mitogen-activated protein kinase dependent pathways, improving metabolic and vascular actions of insulin. SUMMARY: Pathway-specific impairment in insulin action contributes to reciprocal relationships between endothelial dysfunction and insulin resistance, fostering clustering of metabolic and cardiovascular diseases in insulin-resistant states. Therapeutic interventions that target this selective impairment often simultaneously improve both metabolic and vascular function.
Authors: Nathan T Jenkins; Jaume Padilla; Jeffrey S Martin; Jacqueline M Crissey; John P Thyfault; R Scott Rector; M Harold Laughlin Journal: Exp Physiol Date: 2013-08-30 Impact factor: 2.969
Authors: Catherine R Mikus; Seth T Fairfax; Jessica L Libla; Leryn J Boyle; Lauro C Vianna; Douglas J Oberlin; Grace M Uptergrove; Shekhar H Deo; Areum Kim; Jill A Kanaley; Paul J Fadel; John P Thyfault Journal: J Appl Physiol (1985) Date: 2011-07-07
Authors: Guido Lastra; Sofia Syed; L Romayne Kurukulasuriya; Camila Manrique; James R Sowers Journal: Endocrinol Metab Clin North Am Date: 2013-12-12 Impact factor: 4.741
Authors: A M Quintela; R Jiménez; L Piqueras; M Gómez-Guzmán; J Haro; M J Zarzuelo; A Cogolludo; M J Sanz; M Toral; M Romero; F Pérez-Vizcaíno; J Duarte Journal: Br J Pharmacol Date: 2014-06 Impact factor: 8.739
Authors: Netta Lummela; Riina A Kekkonen; Tiina Jauhiainen; Taru K Pilvi; Tuula Tuure; Salme Järvenpää; Johan G Eriksson; Riitta Korpela Journal: Nutr J Date: 2009-10-01 Impact factor: 3.271